Tilray Brands Inc banner

Tilray Brands Inc
NASDAQ:TLRY

Watchlist Manager
Tilray Brands Inc Logo
Tilray Brands Inc
NASDAQ:TLRY
Watchlist
Price: 7.87 USD 14.22% Market Closed
Market Cap: $917.2m

EV/EBITDA

28.7
Current
238%
More Expensive
vs 3-y average of 8.5

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
28.7
=
Enterprise Value
$831.6m
/
EBITDA
$33.9m

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
28.7
=
Enterprise Value
$831.6m
/
EBITDA
$33.9m

Valuation Scenarios

Tilray Brands Inc is trading above its 3-year average

If EV/EBITDA returns to its 3-Year Average (8.5), the stock would be worth $2.33 (70% downside from current price).

Statistics
Positive Scenarios
0/3
Maximum Downside
-70%
Maximum Upside
No Upside Scenarios
Average Downside
62%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 28.7 $7.87
0%
3-Year Average 8.5 $2.33
-70%
Industry Average 10.1 $2.76
-65%
Country Average 14.4 $3.94
-50%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
$831.6m
/
Mar 2026
$33.9m
=
28.7
Current
$831.6m
/
May 2026
$63.8m
=
13
Forward
$831.6m
/
May 2027
$83.4m
=
10
Forward
$831.6m
/
May 2028
$107.2m
=
7.8
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
US
Tilray Brands Inc
NASDAQ:TLRY
917.2m USD 28.7 -0.7
US
Eli Lilly and Co
NYSE:LLY
870.6B USD 28.5 42.2
US
Johnson & Johnson
NYSE:JNJ
544.4B USD 16.6 25.9
CH
Roche Holding AG
SIX:ROG
248.4B CHF 11.6 19.6
UK
AstraZeneca PLC
LSE:AZN
225.4B GBP 16.2 29.2
CH
Novartis AG
SIX:NOVN
222.8B CHF 12.4 20
US
Merck & Co Inc
NYSE:MRK
279.4B USD 9.6 15.3
IE
Endo International PLC
LSE:0Y5F
244.4B USD 386.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 8 10.8
US
Pfizer Inc
NYSE:PFE
152.4B USD 7.6 19.6
US
Bristol-Myers Squibb Co
NYSE:BMY
118.4B USD 7.1 16.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Tilray Brands Inc
NASDAQ:TLRY
Average EV/EBITDA: 48.5
28.7
61%
0.5
US
Eli Lilly and Co
NYSE:LLY
28.5
21%
1.4
US
Johnson & Johnson
NYSE:JNJ
16.6
8%
2.1
CH
Roche Holding AG
SIX:ROG
11.6
6%
1.9
UK
AstraZeneca PLC
LSE:AZN
16.2
12%
1.3
CH
Novartis AG
SIX:NOVN
12.4
5%
2.5
US
Merck & Co Inc
NYSE:MRK
9.6
4%
2.4
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8
2%
4
US
Pfizer Inc
NYSE:PFE
7.6
-8%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A
P/E Multiple
Earnings Growth PEG
US
Tilray Brands Inc
NASDAQ:TLRY
Average P/E: 22.2
Negative Multiple: -0.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.2
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
25.9
8%
3.2
CH
Roche Holding AG
SIX:ROG
19.6
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
29.2
25%
1.2
CH
Novartis AG
SIX:NOVN
20
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.3
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.6
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

Higher than 78% of companies in the United States of America
Percentile
78th
Based on 9 875 companies
78th percentile
28.7
Low
0 — 10
Typical Range
10 — 21.5
High
21.5 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 10
Median 14.4
70th Percentile 21.5
Max 1 767 274.1

Tilray Brands Inc
Glance View

Tilray Brands Inc. emerged on the cannabis scene as a formidable player, carving its niche in a highly volatile yet promising industry. Founded amidst the wave of cannabis legalization sweeping across North America, Tilray quickly became one of the first companies to go public on a major U.S. stock exchange. The company has built its reputation through strategic mergers and acquisitions, most notably its merger with Aphria in 2021, which positioned it as a global leader with comprehensive scale and operational efficiencies. Headquartered in Canada, Tilray has extended its reach with production and distribution facilities not only in the Americas but also across Europe and Australia, capitalizing on the burgeoning medical cannabis market and expanding adult-use sectors. Its array of products spans from dried cannabis flowers and oils to edibles and beverages, catering to diverse consumer needs. Tilray's core business model hinges on a vertically integrated approach, which enables it to oversee the entire supply chain – from cultivation and processing to distribution and sales. This model not only enhances product consistency and quality control but also improves margins by reducing dependency on third-party suppliers. The company primarily generates revenue through its extensive portfolio of brand offerings, including medical-grade products for healthcare providers and recreational products for consumers. Additionally, it has embraced strategic partnerships and diversified into the consumer health and wellness space, venturing into hemp-based foods and alcoholic beverages. By leveraging its global infrastructure and brand strength, Tilray continues to navigate the evolving regulatory landscapes, aiming to capture a significant share of the cannabis industry's projected growth.

TLRY Intrinsic Value
6.63 USD
Overvaluation 16%
Intrinsic Value
Price $7.87
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett